# PF-03446962 in Relapsed or Refractory Urothelial Cancer

> **NCT01620970** · PHASE2 · COMPLETED · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 14 (actual)

## Conditions studied

- Transitional Cell Carcinoma of Bladder

## Interventions

- **DRUG:** PF03446962

## Key facts

- **NCT ID:** NCT01620970
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-01
- **Primary completion:** 2013-06-01
- **Final completion:** 2013-06-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2021-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01620970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01620970, "PF-03446962 in Relapsed or Refractory Urothelial Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01620970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*